The effect of ethnicity on outcome in systemic sclerosis (SSc) is not well understood. The hypothesis to be tested in this proposal is that SSc is a more aggressive disease in non-Caucasians, who manifest a higher occurrence of critical organ involvement and a worse prognosis, and that reasons for this may include genetic factors as well as sociodemographic or behavioral determinants. Therefore, the investigators will: 1) select a well-defined cohort of Caucasians, Hispanics and African Americans (approximately 80 Caucasians, 40-50 African Americans and 40-50 Hispanics) with SSc of five years or less in duration from SSc patients seen at 3 southern Texas medical centers in order to ascertain their initial status and follow their course and early outcome at regular intervals for a period of at least three years; 2) determine the HLA class II genotypes as well as disease-associated alleles of other candidate genes found to be associated with SSc (eg fibrillin, Interleukin 1 receptor antagonist, DNA topoisomerase I and others); 3) determine the sociodemographic parameters of these patients; 4) determine pertinent clinical and laboratory paramenters, including disease manifestations, laboratory features and selected SSc-associated autoantibodies; 5) follow disease progression to outcomes as manifested by: a) development of end-stage pulmonary fibrosis, b) end-stage scleroderma-related renal disease, c) scleroderma heart disease, d) scleroderma-related gastrointestinal involvement, e) MD global assessment of disease severity, f) functional disability, or g) death; 6) examine the relative contributions and interactions of genetic, demographic, socioeconomic, cultural, and initial clinical and laboratory features on the course and outcome of early SSc. Elucidation of those factors affecting outcome in SSc will not only permit modification thereof, but also the identification of high-risk patients to whom earlier and more aggressive therapy could be rendered, which may ultimately improve the prognosis of this disease.

Project Start
1999-12-01
Project End
2001-02-28
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
15
Fiscal Year
2000
Total Cost
$11,128
Indirect Cost
City
Houston
State
TX
Country
United States
Zip Code
77225
Chappell, Cynthia L; Darkoh, Charles; Shimmin, Lawrence et al. (2016) Fecal Indole as a Biomarker of Susceptibility to Cryptosporidium Infection. Infect Immun 84:2299-306
Liao, George P; Harting, Matthew T; Hetz, Robert A et al. (2015) Autologous bone marrow mononuclear cells reduce therapeutic intensity for severe traumatic brain injury in children. Pediatr Crit Care Med 16:245-55
Arroyo-Ávila, Mariangelí; Santiago-Casas, Yesenia; McGwin Jr, Gerald et al. (2015) Clinical associations of anti-Smith antibodies in PROFILE: a multi-ethnic lupus cohort. Clin Rheumatol 34:1217-23
Chappell, Cynthia L; Okhuysen, Pablo C; Langer-Curry, Rebecca C et al. (2015) Cryptosporidium muris: infectivity and illness in healthy adult volunteers. Am J Trop Med Hyg 92:50-5
Reveille, John D (2014) An update on the contribution of the MHC to AS susceptibility. Clin Rheumatol 33:749-57
Bethi, Siddharth; Dasgupta, Abhijit; Weisman, Michael H et al. (2013) Functional limitations due to axial and peripheral joint impairments in patients with ankylosing spondylitis: are focused measures more informative? Arthritis Care Res (Hoboken) 65:607-14
Ward, Michael M; Learch, Thomas J; Gensler, Lianne S et al. (2013) Regional radiographic damage and functional limitations in patients with ankylosing spondylitis: differences in early and late disease. Arthritis Care Res (Hoboken) 65:257-65
Benjamin-Garner, Ruby; Stotts, Angela (2013) Impact of smoking exposure change on infant birth weight among a cohort of women in a prenatal smoking cessation study. Nicotine Tob Res 15:685-92
Ornstein, Tisha J; Max, Jeffrey E; Schachar, Russell et al. (2013) Response inhibition in children with and without ADHD after traumatic brain injury. J Neuropsychol 7:1-11
Murthy, Vijaya; Willis, Rohan; Romay-Penabad, Zurina et al. (2013) Value of isolated IgA anti-?2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum 65:3186-93

Showing the most recent 10 out of 396 publications